AstraZeneca paid USD$ 5.5 Billion to co-market Enhertu
March 2019 - AstraZeneca entered into a global development and commercialisation collaboration agreement with Daiichi Sankyo Company, Limited (Daiichi Sankyo) for trastuzumab deruxtecan (DS-8201) (Enhertu), a proprietary antibody-drug conjugate (ADC) a targeted medicine for cancer treatment.
Under the terms of the agreement, AstraZeneca paid Daiichi Sankyo an upfront payment of $1.35bn.